Organization · Venture Capital
Mountainfield Venture Partners
Mountainfield Venture Partners is a San Diego-based firm that builds new companies around development-stage drug candidates in the biopharmaceutical sector. They focus on in-licensing drug candidates and assembling leadership teams to transform patient care.
Overview
What Mountainfield Venture Partners does
What Mountainfield Venture Partners is
Mountainfield Venture Partners is a San Diego-based firm that builds new companies around development-stage drug candidates in the biopharmaceutical sector. They focus on in-licensing drug candidates and assembling leadership teams to transform patient care.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2024
- Approximate age
- About 2 years
- Structured capabilities
- Funder
- Last reviewed
- April 25, 2026
Official channels
Find Mountainfield Venture Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Mountainfield Venture Partners as a funder
Investment thesis
Mountainfield Venture Partners focuses on building new companies around development-stage drug candidates aimed at transforming patient care. They leverage in-licensed drug candidates and assemble world-class leadership teams to drive innovation in biopharmaceuticals.
Focus narrative
Mountainfield Venture Partners invests in the biopharmaceutical sector, specifically targeting development-stage drug candidates. The organization emphasizes the formation of companies that leverage in-licensed assets, aiming to establish operational strategies based on extensive experience in both small start-up biotechnology firms and multinational pharmaceutical companies.
Value beyond capital
Mountainfield Venture Partners adds value by forming companies around in-licensed drug candidates and assembling world-class leadership teams. Their extensive experience in biopharmaceuticals allows them to create operational strategies that enhance the potential for success in the development of transformative therapies.
Focus and fit
- Stages
- Seed · Series A · Series A+
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 15
- Recorded notable exits
- Myovant, Phathom Pharmaceuticals, Day One Pharmaceuticals, Arcutis, HilleVax, and Passage Bio
Portfolio context
Mountainfield has co-founded over 15 venture-backed life sciences companies, leading to six NASDAQ IPOs and eight FDA-approved drug products. Notable portfolio companies include Myovant (NASDAQ: MYOV), Phathom Pharmaceuticals (NASDAQ: PHAT), Day One Pharmaceuticals (NASDAQ: DAWN), Arcutis (NASDAQ: ARQT), HilleVax (NASDAQ: HLVX), and Passage Bio (NASDAQ: PASG). Their flagship company, Timberlyne Therapeutics, raised $180M in a Series A round to develop a monoclonal antibody for autoimmune disorders.
Common questions
What to know about Mountainfield Venture Partners
Upseed classifies Mountainfield Venture Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 25, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.